These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 31440738)

  • 1. Genomic Correlates of Exceptional Response to ErbB3 Inhibition in Head and Neck Squamous Cell Carcinoma.
    Faden DL; Gomez-Casal R; Alvarado D; Duvvuri U
    JCO Precis Oncol; 2019; 3():. PubMed ID: 31440738
    [No Abstract]   [Full Text] [Related]  

  • 2. Anti-Trop2 blockade enhances the therapeutic efficacy of ErbB3 inhibition in head and neck squamous cell carcinoma.
    Redlich N; Robinson AM; Nickel KP; Stein AP; Wheeler DL; Adkins DR; Uppaluri R; Kimple RJ; Van Tine BA; Michel LS
    Cell Death Dis; 2018 Jan; 9(1):5. PubMed ID: 29305574
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ErbB3, a possible prognostic factor of head and neck squamous cell carcinoma.
    Kim H; Choi JY; Rah YC; Ahn JC; Kim H; Jeong WJ; Ahn SH
    Oral Surg Oral Med Oral Pathol Oral Radiol; 2020 Apr; 129(4):377-387. PubMed ID: 32081558
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gene alterations as predictors of radiation-induced toxicity in head and neck squamous cell carcinoma.
    Sumner W; Ray X; Sutton L; Rebibo D; Marincola F; Sanghvi P; Moiseenko V; Deichaite I
    J Transl Med; 2021 May; 19(1):212. PubMed ID: 34001187
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular and Clinical Activity of CDX-3379, an Anti-ErbB3 Monoclonal Antibody, in Head and Neck Squamous Cell Carcinoma Patients.
    Duvvuri U; George J; Kim S; Alvarado D; Neumeister VM; Chenna A; Gedrich R; Hawthorne T; LaVallee T; Grandis JR; Bauman JE
    Clin Cancer Res; 2019 Oct; 25(19):5752-5758. PubMed ID: 31308059
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cell-free mitochondrial DNA copy number variation in head and neck squamous cell carcinoma: A study of non-invasive biomarker from Northeast India.
    Kumar M; Srivastava S; Singh SA; Das AK; Das GC; Dhar B; Ghosh SK; Mondal R
    Tumour Biol; 2017 Oct; 39(10):1010428317736643. PubMed ID: 29072129
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neuregulin Signaling Is a Mechanism of Therapeutic Resistance in Head and Neck Squamous Cell Carcinoma.
    Baro M; Lopez Sambrooks C; Burtness BA; Lemmon MA; Contessa JN
    Mol Cancer Ther; 2019 Nov; 18(11):2124-2134. PubMed ID: 31387891
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ERBB3/HER2 signaling promotes resistance to EGFR blockade in head and neck and colorectal cancer models.
    Zhang L; Castanaro C; Luan B; Yang K; Fan L; Fairhurst JL; Rafique A; Potocky TB; Shan J; Delfino FJ; Shi E; Huang T; Martin JH; Chen G; Macdonald D; Rudge JS; Thurston G; Daly C
    Mol Cancer Ther; 2014 May; 13(5):1345-55. PubMed ID: 24634416
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genomic Correlate of Exceptional Erlotinib Response in Head and Neck Squamous Cell Carcinoma.
    Van Allen EM; Lui VW; Egloff AM; Goetz EM; Li H; Johnson JT; Duvvuri U; Bauman JE; Stransky N; Zeng Y; Gilbert BR; Pendleton KP; Wang L; Chiosea S; Sougnez C; Wagle N; Zhang F; Du Y; Close D; Johnston PA; McKenna A; Carter SL; Golub TR; Getz G; Mills GB; Garraway LA; Grandis JR
    JAMA Oncol; 2015 May; 1(2):238-44. PubMed ID: 26181029
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HDAC inhibitor vorinostat enhances the antitumor effect of gefitinib in squamous cell carcinoma of head and neck by modulating ErbB receptor expression and reverting EMT.
    Bruzzese F; Leone A; Rocco M; Carbone C; Piro G; Caraglia M; Di Gennaro E; Budillon A
    J Cell Physiol; 2011 Sep; 226(9):2378-90. PubMed ID: 21660961
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exceptional Response to PD-1 Blockade as First-Line Therapy in Head and Neck Squamous Cell Carcinoma.
    Kumai T; Komatsuda H; Minami Y; Harabuchi Y
    ORL J Otorhinolaryngol Relat Spec; 2020; 82(6):343-350. PubMed ID: 32882699
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ErbB activation signatures as potential biomarkers for anti-ErbB3 treatment in HNSCC.
    Alvarado D; Ligon GF; Lillquist JS; Seibel SB; Wallweber G; Neumeister VM; Rimm DL; McMahon G; LaVallee TM
    PLoS One; 2017; 12(7):e0181356. PubMed ID: 28723928
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells.
    Erjala K; Sundvall M; Junttila TT; Zhang N; Savisalo M; Mali P; Kulmala J; Pulkkinen J; Grenman R; Elenius K
    Clin Cancer Res; 2006 Jul; 12(13):4103-11. PubMed ID: 16818711
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    Costa EFD; Lima TRP; Lopes-Aguiar L; Nogueira GAS; Visacri MB; Quintanilha JCF; Pincinato EC; Calonga L; Mariano FV; Altemani AMAM; Altemani JMC; Moriel P; Chone CT; Ramos CD; Lima CSP
    Tumour Biol; 2020 Jul; 42(7):1010428320938494. PubMed ID: 32628088
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dysregulation of hypoxia inducible factor-1alpha in head and neck squamous cell carcinoma cell lines correlates with invasive potential.
    Cohen NA; Lai SY; Ziober AF; Ziober BL
    Laryngoscope; 2004 Mar; 114(3):418-23. PubMed ID: 15091212
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Personalized Medicine Approach for an Exceptional Response to Multiple-recurrent and Metastatic HER2-positive Oropharyngeal Squamous Cell Carcinoma.
    Seim NB; Kang SY; Bhandari M; Jones RG; Teknos TN
    Ann Otol Rhinol Laryngol; 2017 Apr; 126(4):334-339. PubMed ID: 28061634
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ErbB receptors and fatty acid synthase expression in aggressive head and neck squamous cell carcinomas.
    Silva SD; Cunha IW; Younes RN; Soares FA; Kowalski LP; Graner E
    Oral Dis; 2010 Nov; 16(8):774-80. PubMed ID: 20604875
    [TBL] [Abstract][Full Text] [Related]  

  • 18. AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor, ERBB2 (HER2), and ERBB3: a unique agent for simultaneous ERBB receptor blockade in cancer.
    Hickinson DM; Klinowska T; Speake G; Vincent J; Trigwell C; Anderton J; Beck S; Marshall G; Davenport S; Callis R; Mills E; Grosios K; Smith P; Barlaam B; Wilkinson RW; Ogilvie D
    Clin Cancer Res; 2010 Feb; 16(4):1159-69. PubMed ID: 20145185
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ErbB3 upregulation by the HNSCC 3D microenvironment modulates cell survival and growth.
    Humtsoe JO; Pham E; Louie RJ; Chan DA; Kramer RH
    Oncogene; 2016 Mar; 35(12):1554-64. PubMed ID: 26073080
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comprehensive genomic profiling of head and neck squamous cell carcinoma reveals FGFR1 amplifications and tumour genomic alterations burden as prognostic biomarkers of survival.
    Dubot C; Bernard V; Sablin MP; Vacher S; Chemlali W; Schnitzler A; Pierron G; Ait Rais K; Bessoltane N; Jeannot E; Klijanienko J; Mariani O; Jouffroy T; Calugaru V; Hoffmann C; Lesnik M; Badois N; Berger F; Le Tourneau C; Kamal M; Bieche I
    Eur J Cancer; 2018 Mar; 91():47-55. PubMed ID: 29331751
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.